NCT01071070 - Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease | Biotech Hunter

Enrollment

216

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Chronic Kidney Disease

Interventions

DRUG

paricalcitol

Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.

Trial Locations (12)

100034

Site Reference ID/Investigator# 23483, Beijing

100044

Site Reference ID/Investigator# 23485, Beijing

100730

Site Reference ID/Investigator# 23482, Beijing

116011

Site Reference ID/Investigator# 23484, Dalian

200001

Site Reference ID/Investigator# 23490, Shanghai

Site Reference ID/Investigator# 25502, Shanghai

200025

Site Reference ID/Investigator# 23489, Shanghai

200092

Site Reference ID/Investigator# 23487, Shanghai

210029

Site Reference ID/Investigator# 23488, Nanjing

266003

Site Reference ID/Investigator# 37722, Qingdao

325000

Site Reference ID/Investigator# 35822, Wenzhou

510080

Site Reference ID/Investigator# 23486, Guangzhou